利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

44 条记录 (耗时 0.04 秒)

    Inhibition of interleukin-1 production by monocytes and/or macrophages
    2.
    发明授权
    Inhibition of interleukin-1 production by monocytes and/or macrophages 失效
    单核细胞和/或巨噬细胞抑制白细胞介素1的产生

    公开(公告)号：US4778806A

    公开(公告)日：1988-10-18

    申请号：US898447

    申请日：1986-08-19

    申请人： Paul E. Bender ,  Don E. Griswold ,  Nabil Hanna ,  John C. Lee

    发明人： Paul E. Bender ,  Don E. Griswold ,  Nabil Hanna ,  John C. Lee

    IPC分类号： A61K31/44

    CPC分类号： A61K31/44

    摘要： A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such human an effective interleukin-1 production inhibiting amount of a 2-2'-[1,3-propan-2-onediyl-bis(thio)]bis-1H-imidazole or a pharmaceutically acceptable salt thereof.

    摘要翻译： 一种抑制有需要的人中单核细胞和/或巨噬细胞产生白细胞介素-1的方法，其包括向所述人施用有效的白细胞介素-1产生抑制量的2-2' - [1,3-丙 - （硫代）]双-1H-咪唑或其药学上可接受的盐。

    Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
    4.
    发明授权
    Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages 失效
    单核细胞和/或巨噬细胞抑制白细胞介素-1和肿瘤坏死因子的产生

    公开(公告)号：US5317019A

    公开(公告)日：1994-05-31

    申请号：US809484

    申请日：1991-12-12

    申请人： Paul E. Bender ,  Don E. Griswold ,  Nabil Hanna ,  John C. Lee ,  Bartholomew J. Votta ,  Philip L. Simon ,  Alison M. Badger ,  Klaus M. Esser

    发明人： Paul E. Bender ,  Don E. Griswold ,  Nabil Hanna ,  John C. Lee ,  Bartholomew J. Votta ,  Philip L. Simon ,  Alison M. Badger ,  Klaus M. Esser

    IPC分类号： A61K31/42 ,  A61K31/425 ,  A61K31/435 ,  A61K31/44 ,  A61K31/54 ,  A61K31/55 ,  A61P29/00 ,  A61P43/00 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D513/04 ,  A01N43/40

    CPC分类号： C07D471/04 ,  A61K31/44 ,  C07D487/04 ,  C07D513/04

    摘要： A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such a human an effective, interleukin-1 production inhibiting amount of a diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead atom wherein said second ring may also contain sulfur, oxygen or an additional nitrogen atom, and may contain additional unsaturation.This invention relates to a method of inhibiting the production of Tumor Necrosis Factor (TNF) by monocytes or macrophages in a human in need thereof which comprises administering to such mammal an effective, TNF production inhibiting amount of a compound of Formula (I) as described herein. The compounds of Formula (II) are generally described as diaryl-substituted imidazole fused to a second heterocyclic ring containing a nitrogen bridgehead wherein said ring may also contain sulfur, oxygen, or an additional nitrogen atom, and may contain additional unsaturation.

    摘要翻译： PCT No.PCT / US90 / 03367 Sec。 371日期1991年12月12日 102（e）1991年12月12日授权PCT于1990年6月13日提交.1。一种在有需要的人中抑制单核细胞和/或巨噬细胞产生白细胞介素-1的方法，其包括给予这样一种有效的， 与含有氮桥头原子的第二杂环稠合的二芳基取代的咪唑的白细胞介素-1产生抑制量，其中所述第二环还可以含有硫，氧或另外的氮原子，并且可以含有额外的不饱和度。 本发明涉及在有需要的人中抑制单核细胞或巨噬细胞产生肿瘤坏死因子（TNF）的方法，该方法包括向所述哺乳动物施用有效的TNF产生抑制量的如上所述的式（I）化合物 这里。 式（II）的化合物通常被描述为与包含氮桥头堡的第二杂环稠合的二芳基取代的咪唑，其中所述环还可以含有硫，氧或另外的氮原子，并且可以含有额外的不饱和度。

    MOBILE COMMUNICATIONS
    5.
    发明申请
    MOBILE COMMUNICATIONS 有权
    移动通信

    公开(公告)号：US20090116466A1

    公开(公告)日：2009-05-07

    申请号：US12299979

    申请日：2007-04-18

    申请人： John C. Lee ,  Geoffrey T. Haigh ,  David E. Hughes ,  Andrew RJ Cook

    发明人： John C. Lee ,  Geoffrey T. Haigh ,  David E. Hughes ,  Andrew RJ Cook

    IPC分类号： H04W40/02

    CPC分类号： H04W8/02 ,  H04W8/26 ,  H04W84/042 ,  H04W88/06 ,  H04W92/02

    摘要： A mobile communications handset (12) is capable of connection through two different networks (2, 27). When it is out of contact with its preferred local wireless access system (27), the handset will seek a hand-over to the cellular network (2), and will become registered as a “roaming” handset currently connected to the cellular network (2). The cellular network (2) reports this location information to the call server (28), as it would to the HLR of any normal visiting handset, so that incoming calls to the PSTN (6) destined for the user (12) can be routed by way of the cellular network. Outgoing calls are handled as conventional cellular telephony calls. When contact with a local wireless access system (27) is re-established, the contact information is passed to the call server 28, which reports to the cellular network (2) that a handover has occurred. An interface between the call server (28) and cellular network (2) is configured such that the call server (28) emulates a base site controller of the cellular network (2). The cellular network therefore operates conventionally, with the handset (12) logged as operating through this quasi-base site controller. However, the cellular system would continue to register the presence of the handset as co-operating with the quasi-base station (28), even though it would have no visibility of most calls being made to and from the handset (12). This avoids the cellular system (2) attempting to seize control of the handset through a normal cellular base station (21).

    摘要翻译： 移动通信手机（12）能够通过两个不同的网络（2,27）进行连接。 当它与其优选的本地无线接入系统（27）不接触时，手机将寻求对蜂窝网络（2）的切换，并且将被注册为当前连接到蜂窝网络的“漫游”手机（ 2）。 蜂窝网络（2）向呼叫服务器（28）报告该位置信息，就像对任何正常访问手机的HLR一样，从而可以将去往用户（12）的PSTN（6）的呼入路由 通过蜂窝网络。 拨出呼叫作为传统蜂窝电话呼叫处理。 当与本地无线接入系统（27）的接触被重新建立时，联系信息被传递给呼叫服务器28，呼叫服务器28向蜂窝网络（2）报告发生了切换。 呼叫服务器（28）和蜂窝网络（2）之间的接口被配置为使得呼叫服务器（28）模拟蜂窝网络（2）的基站控制器。 蜂窝网络因此常规地操作，手机（12）通过该准基地点控制器记录为操作。 然而，蜂窝系统将继续将手机的存在注册为与准基站（28）合作，即使它对于进入和从手机（12）进行的大部分呼叫都不具有可见性。 这避免了蜂窝系统（2）尝试通过正常的蜂窝基站（21）来占用手机的控制。

    Walking cane
    7.
    外观设计
    Walking cane 失效
    徒步拐杖

    公开(公告)号：USD473707S1

    公开(公告)日：2003-04-29

    申请号：US29166591

    申请日：2002-08-30

    申请人： John C. Lee

    设计人： John C. Lee

    Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
    8.
    发明授权
    Compositions and therapeutic methods using morphogenic proteins and stimulatory factors 失效
    使用形态发生蛋白和刺激因子的组合物和治疗方法

    公开(公告)号：US6048964A

    公开(公告)日：2000-04-11

    申请号：US570752

    申请日：1995-12-12

    申请人： John C. Lee ,  Lee-Chuan C. Yeh

    发明人： John C. Lee ,  Lee-Chuan C. Yeh

    IPC分类号： C12N15/09 ,  A61K31/00 ,  A61K31/20 ,  A61K31/202 ,  A61K31/565 ,  A61K31/57 ,  A61K31/573 ,  A61K31/59 ,  A61K38/00 ,  A61K38/18 ,  A61K38/27 ,  A61K38/28 ,  A61K38/30 ,  A61L24/10 ,  A61L27/00 ,  A61L27/22 ,  A61P19/00 ,  A61P43/00 ,  C12N5/10 ,  C12N7/00 ,  C12P21/02

    CPC分类号： A61L27/227 ,  A61K38/1875 ,  A61K38/30 ,  A61L24/108

    摘要： The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins, particularly those belonging to the BMP protein family. Methods for improving the tissue inductive activity of a morphogenic protein in a mammal using those compositions are provided. This invention also provides implantable morphogenic devices comprising a morphogenic protein and a MPSF disposed within a carrier, that are capable of inducing tissue formation in allogeneic and xenogeneic implants. Methods for inducing local tissue formation from a progenitor cell in a mammal using those devices are also provided. A method for accelerating allograft repair in a mammal using morphogenic devices is provided. This invention also provides a prosthetic device comprising a prosthesis coated with a morphogenic protein and a MPSF, and a method for promoting in vivo integration of an implantable prosthetic device to enhance the bond strength between the prosthesis and the existing target tissue at the joining site. Methods of treating tissue degenerative conditions in a mammal using the pharmaceutical compositions are also provided.

    摘要翻译： 本发明提供包含形态发生蛋白质刺激因子（MPSF）的药物组合物，用于改善形态发生蛋白质，特别是属于BMP蛋白质家族的组织诱导活性。 提供了使用这些组合物改善哺乳动物中形态发生蛋白的组织诱导活性的方法。 本发明还提供了可植入形态发生装置，其包含形态发生蛋白和设置在载体内的MPSF，其能够诱导同种异体和异种植入物中的组织形成。 还提供了使用这些装置从哺乳动物的祖细胞诱导局部组织形成的方法。 提供了使用形态发生装置促进哺乳动物同种异体移植修复的方法。 本发明还提供了一种假体装置，其包括涂覆有形态发生蛋白质和MPSF的假体，以及用于促进可植入假体装置的体内整合以增强假体和接合部位的现有靶组织之间的结合强度的方法。 还提供了使用药物组合物治疗哺乳动物的组织退行病症的方法。